Advances in Leishmaniasis and Chagas Disease: Biology, Epidemiology, Treatment and Control
A special issue of Biology (ISSN 2079-7737). This special issue belongs to the section "Microbiology".
Deadline for manuscript submissions: 15 August 2025 | Viewed by 10037
Special Issue Editors
Interests: immunology; pharmacology; pathology; inflammation; immunomodulators; Leishmaniasis; tumor; cellular biology; molecular biology; biochemistry
Interests: leishmaniasis; Chagas disease; immunopathology; diagnosis; treatment; epidemiology; molecular biology
Special Issues, Collections and Topics in MDPI journals
Interests: Leishmaniasis; Chagas disease; inflammation; host-pathogen interaction; extracellular matrix; immunopathology; toxoplasmosis; vaccine; treatment, murine model
Special Issue Information
Dear Colleagues,
Leishmaniasis and Chagas disease are neglected tropical diseases, prevalent in tropical regions, especially developing countries. Leishmaniases are a group of diseases that affects around 700,000 to 1 million people worldwide annually. Chagas disease is caused by Trypanosoma cruzi, and it is estimated that there are about 6 to 7 million people infected with it worldwide. In Brazil, visceral leishmaniasis is considered one of the top parasitic diseases with outbreak and mortality potential, while Chagas disease is the fourth cause of death resulting from infectious and parasitic diseases. Clinical outcomes of both diseases depend on the complexity of the factors involved, related both to the parasite (genetic variability, inoculum, infectivity, pathogenicity, virulence, and inoculation pathways) and to the host (age, sex, nutrition, immune profile, and species). Few effective therapeutic options are available for both diseases, with considerable side effects and long treatment periods, in addition to an increasing development of parasite resistance to the drugs in current use. The complexity of the factors involved in the immunopathology of both Leishmaniasis and Chagas disease influences the disease pathogenesis, chemotherapy outcome, and control, highlighting the need for further studies to improve our understanding of these relationships.
This Special Issue aims to report new insights into interdisciplinary approaches covering host–parasite and vector interaction, immune response of hosts, new molecular pathways for parasite survival and persistence, new drug development and mechanisms of antiparasitic drugs, as well as control, epidemiology, and vaccine development. Studies focusing on immunopathogeny and diagnosis, host defense, survival–resistance mechanisms, host–pathogen interactions, immune response, virulence factors, molecular diagnosis, immunological diagnosis, drug and vaccine development, pharmacological resistance, phytotherapy, synthetic compounds, drug repurposing, mechanisms of action, toxicology, preclinical trials, vaccine adjuvant, vaccine antigen, antibody, clinical and epidemiological insights, clinical manifestations, risk factors, distribution, ecology transmission, life cycle, wild cycle, reservoirs, and species taxonomy are welcome. We envision that this Special Issue will introduce valuable insights regarding Leishmaniasis and Chagas disease management.
Prof. Dr. Fernando Almeida-Souza
Dr. Flávia de Oliveira Cardoso
Dr. Kátia Da Silva Calabrese
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Leishmaniasis
- Chagas disease
- immunopathogeny
- diagnosis
- epidemiology
- control
- clinical studies
- treatment
- vaccine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.